Download Free Medical Familial Cancer Risk Assessment Colorectal Cancer PowerPoint Presentation

Familial Cancer Risk Assessment Colorectal Cancer PowerPoint Presentation

DOWNLOAD MEDICAL POWERPOINT PRESENTATION

About This Presentation

Description : This medical presentation on cancer titled "Familial Cancer Risk Assessment Colorectal Cancer" presents case on Familial Cancer Risk Assessment Colorectal Cancer.

Tags : Cancer, Familial Cancer Risk Assessment, Colorectal Cancer, Hereditary colorectal cancer syndromes, Hereditary CRC syndromes, Lynch syndrome

Published on : Apr 28, 2021 | Views : 1070 | Downloads : 2

Shareable Url :

Embed Code :

Comment

Transcript

Slide 1-

Genetics and Primary Care Familial Cancer Risk Assessment Colorectal Cancer
Slide 2-

Case 1:Joan Joan, age 38, was recently diagnosed with endometrial cancer. Family history reveals: Paternal grandmother: endometrial cancer, age 50 Paternal uncle: colon cancer, age 48 Father: colonoscopy at age 50; four adenomatous polyps removed No other significant history Both sides of the family are Northern European Caucasian
Slide 3-

Case 2: Ted Ted is 30 and wants a colonoscopy because his mother was just diagnosed with colon cancer after routine screening at age 54. Family history reveals: Paternal grandfather: died of CRC at age 79 No hx of endometrial, ovarian, small bowel or ureter/kidney cancer on either side of family Two maternal aunts: cervical cancer at ages 30 & 34 Maternal grandmother: breast cancer age 85
Slide 4-

Outline Hereditary colorectal cancer syndromes Cancer family history – a primary tool Evaluating your patients for familial CRC risk Genetic counseling and testing for hereditary colorectal cancer How, when, where to refer patients for genetic services
Slide 5-

Colorectal Cancer ~5-8% of all cases of CRC are hereditary ~15-20% are “familial” / multifactorial ~75% of cases are sporadic Feuer EJ: DEVCAN: National CA Inst. 1999
Slide 6-

Characteristics of Average Risk No well-defined threshold between sporadic and familial CRC at this time Probably safe to include individuals with: No personal risk factors or family history of CRC One 2nd or 3rd degree relative with CRC >60 years with no other family history of CRC
Slide 7-

Characteristics of “Familial” CRC “Clustering” of colon cancer cases in the family (> 50 at diagnosis) without clear dominant pattern, or One close relative with CRC <60 yrs and family history does not meet criteria for known hereditary CRC syndromes Likely to be multiple low pentrant genes plus environmental factors at play Family members warrant earlier CRC screening Starting at 40 years or 5-10 yrs earlier than age of diagnosis of the youngest affected relative Winawer et al., Gastroenterology 2003:124:544-560
Slide 8-

Characteristics of Hereditary CRC Multiple relatives with colorectal cancer One or more diagnosed at an early age (<50) Sequential generations affected Except in autosomal recessive syndromes Other cancers in the family known to be associated with CRC (uterine, ovarian, GI) Multiple primary tumors or polyps
Slide 9-

Hereditary CRC syndromes Hereditary Non-Polyposis Colorectal Cancer (HNPCC) Variants: Muir-Torre, Turcot Familial Adenomatous Polyposis (FAP) Variants: Gardner, Turcot Attenuated FAP APC mutation in Ashkenazi Jews Others: Multiple adenomatous polyposis syndrome/MYH gene (MAP) Peutz-Jeghers syndrome (PJS) Familial Juvenile Polyposis (FJP)
Slide 10-

In Your Practice: Colon Cancer In the typical primary care practice, 2 to 8 patients (1/200 to 1/800) are from “high risk” families, with a condition called Hereditary Non-Polyposis Colon Cancer (HNPCC). These patients have a high lifetime risk of colorectal and other cancers with risk starting in their 20’s.
Slide 11-

HNPCC: AKA “Lynch syndrome” 2-3% of all colorectal cancer cases Autosomal dominant; high penetrance Typical age of CA onset is 40-50 yrs Multiple affected generations 60-70% right-sided/proximal CRC tumors Polyps may be present, multiple primaries common. Can overlap with AFAP
Slide 12-

HNPCC Lifetime cancer risks: Colorectal 80% Endometrial 20-60% Gastric 13-19% Ovarian 9-12% Biliary tract 2% Urinary tract 4% Small bowel 1-4% Brain/CNS 1-3%
Slide 13-

HNPCC: Clinical Diagnostic Criteria Amsterdam II Criteria (3-2-1 rule) 3 or more relatives with an HNPCC-related cancer, one of whom is a 1st degree relative of the other two 2 or more successive generations affected 1 or more cancers diagnosed before age 50
Slide 14-

HNPCC Caused by mutations or deletions in mismatch repair (MMR) genes MSH2, MLH1, MSH6, (PMS2) 90% of detectable mutations in MSH2 and MLH1 50% of families meeting Amsterdam II Criteria have detectable mutations Testing/screening options: Direct genetic testing of MMR genes (in select families) Initial screening of the tumor tissue by MSI/IHC
Slide 15-

Proceed Directly To Genetic Testing After genetic counseling and informed consent! IF: Family history fulfills Amsterdam II criteria or Patient has two HNPCC related cancers or Patient has CRC and a 1st degree relative with HNPCC-related cancer, with at least one cancer diagnosed <50 years of age Always test an affected family member first!
Slide 16-

MSI/IHC screening Microsatellite Instability (MSI) on tumor tissue can be used to screen for HNPCC in select cases Immunohistochemistry (IHC) on tumor tissue can be used to detect the presence or absence of the mismatch repair proteins (MSH2, MLH1, etc.) “Screen positive” individuals can be offered cancer genetic counseling/assessment and targeted genetic testing
Slide 17-

Criteria for MSI/IHC screening Revised Bethesda Criteria, 2004 CRC or endometrial CA <50 yrs 2 HNPCC cancers in same person CRC with “MSI-H histology” diagnosed <60 yrs Infiltrating lymphocytes, Crohns-like lymphocytic reaction, mucinous/signet ring differentiation, medullary growth pattern CRC and one or more 1st degree relative with an HNPCC-related cancer, one diagnosed <50 yrs CRC and two or more 1st or 2nd degree relatives with HNPCC-related cancers, any age Umar A et al: J Natl Cancer Inst, 2004; 96(4):261-268
Slide 18-

HNPCC Surveillance Gene carriers or at-risk relatives: CRC: colonoscopy age 20-25, repeat 1-2 yrs Women: gyn exam, endometrial aspiration, TV U/S, CA-125 (?) age 25-35, repeat 1-2 yrs If one HNPCC family member affected w/the following: Stomach CA: EGD age 3-35, repeat 1-2 yrs Urinary tract CA: urine cytology age 30-35, repeat 1-2 yrs NCCN practice guidelines in oncology – v.1.2003
Slide 19-

FAP 1 in 10,000 incidence 100’s to 1000’s of colonic adenomas by teens Cancer risk: colon, gastric, duodenum (periampulla), small bowel, pancreas, papillary thyroid, childhood hepatoblastoma 7% risk of CRC by 21 yrs; 93% by 50 yrs Autosomal dominant: APC gene mutations Variants: Gardner, Turcot
Slide 20-

FAP – surveillance Colon Annual sigmoidoscopy, age 10-12 yrs Prophylactic colectomy following polyp detection w/continued surveillance of rectum, ileal pouch Duodenal/gastric EGD age 25, repeat 1-3 yrs Thyroid Annual PE, age 10 Hepatoblastoma Annual screen by abd U/S & AFP from birth to 5 yrs. Gastroenterology 2001; 121: 195. AGA Statement
Slide 21-

Attenuated FAP 20 to 100 polyps, usually more proximal Onset later than FAP, average AOO = 50 Lifetime risk of CRC = 80% Extracolonic tumors occur at same rate as FAP Variant of FAP, mutations in same APC gene Surveillance: annual colonoscopy starting late teens or early 20’s Option of subtotal colectomy
Slide 22-

Genetic Testing: FAP/AFAP Test an affected family member first! After genetic counseling and informed consent APC gene testing can confirm a suspected diagnosis Family members of a person with a known APC mutation can have mutation-specific testing Genetic testing for children at risk for FAP can be considered before beginning colon screening
Slide 23-

APC gene mutation in Ashkenazi Jews Missense mutation (I1307K) associated with increased risk of CRC and adenomas in Ashkenazi Jews (AJ) Found in 6% of the general AJ population 12% of AJs with CRC 29% of AJs with CRC and a positive family history Lifetime risk of CRC in mutation carrier is 10-20% Screening: colonscopy every 2-5 yrs starting at 35 yrs
Slide 24-

MAP syndrome/MYH gene Multiple adenomatous polyposis (MAP) syndrome Autosomal recessive; mutations in the MYH gene Median number of polyps = 55 Mean age of polyp diagnosis = 30-50 years Polyps mainly small, mildly dysplastic tubular adenomas. Some tubulovillous, hyperplastic, serrated adenomas, microadenomas 30% of individuals with 15-100 polyps have homozygous mutations in the MYH gene Genetic testing should be offered if >15 polyps (and APC gene testing negative)
Slide 25-

Peutz-Jeghers syndrome <1% of all CRC cases Hamartomatous polyps of GI tract as early as 1st decade Mucocutaneous hyperpigmentation lips, mouth, buccal mucosa, fingers Usually seen in children < 5 yrs Cancer risk: colon, small intestine, stomach, pancreas, breast, ovaries, uterus, testes, lungs, kidneys Mutations in STK11 gene found in 70% of familial cases and 30-70% of sporadic cases
Slide 26-

Familial Juvenile Polyposis <1% of all CRC cases Autosomal dominant 5 or more juvenile polyps in colon or GI tract Appear in 1st or 2nd decade 50% lifetime risk of CRC; AOO in 30’s Increased risk gastric, GI, pancreatic CA ~50% of cases have mutations in either the MADH4 or BMPR1A genes
Slide 27-

ppt slide no 27 content not found
Slide 28-

What can YOU do?
Slide 29-

CRC Risk Screening: Steps to take Take a thorough cancer family history Does family history meet hereditary criteria? If yes, refer to genetics Classify based on family history: average, moderate or high risk. Create surveillance plan based on risk level
Slide 30-

CRC Risk Screening: Steps to take Take a thorough cancer family history Does family history meet hereditary criteria? If yes, refer to genetics Classify based on family history: average, moderate or high risk. Create surveillance plan based on risk level
Slide 31-

Family Health History “The family tree has become the most important genetic test of all. The more you know, the more tools you have to practice preventive medicine” Donna Russo, Certified Genetic Counselor, NY Presbyterian-Columbia Hospital
Slide 32-

Family History Details to Record Type of primary cancer(s) in each relative Age of disease onset in each relative Cancer status in 1st and 2nd degree relatives Cancer status in both sides of the family Other medical findings
Slide 33-

ppt slide no 33 content not found
Slide 34-

CRC Risk Screening: Steps to take Take a thorough cancer family history Does family history meet ‘potentially hereditary’ criteria? If yes, refer to genetics Classify based on family history: average, moderate or high risk. Create surveillance plan based on risk level
Slide 35-

Consider Genetics Referral for: Two or more family members with CRC* at least one <50 Three or more family members w/CRC*; any age Patient with colon cancer before 40 yrs Endometrial cancer and family history of CRC <50 Persons with more than one primary CRC <50 yrs or with both endometrial CA and CRC Family or personal history of CRC and one or more 1st degree relative with an HNPCC-related cancer, one diagnosed <50 yrs. *Same side of family
Slide 36-

Consider Genetics Referral for: MSI and/or IHC tumor results suspicious for HNPCC Autosomal dominant pattern of cancers in the family Persons with 15 or more adenomatous colorectal polyps Persons with multiple hamartomatous or juvenile GI polyps Persons with a family history of a known hereditary cancer syndrome
Slide 37-

CRC Risk Screening: Steps to take Take a thorough cancer family history Does family history meet hereditary criteria? If yes, refer to genetics Classify based on family history: average, moderate or high risk. Create surveillance plan based on risk level
Slide 38-

Empiric Risk of CRC Risk for CRC based on family history increases with: Closer degree of relationship and # of affected members Younger age of onset Presence of extracolonic tumors, multiple primaries
Slide 39-

Family History: Empiric Risks Lifetime Risk CRC General population in US ~2 to 6% One 1st degree relative w/CRC 2-3 fold Two 1st degree relatives w/CRC 3-4 fold 1st degree relative w/CRC <50 3-4 fold One 2nd or 3rd degree relative w/CRC ~1.5-fold Two 2nd degree relatives w/CRC 2-3 fold
Slide 40-

Goal: Classification Family Hx Assessment Personalized prevention recommendations Referral for genetic evaluation with personalized prevention recommendations Standard prevention recommendations Intervention Average Moderate (“Familial”) High/Genetic Risk Classification
Slide 41-

CRC Risk Management Age to Begin Average Risk 50 yrs No family history CRC OR One 2nd or 3rd degree relative with CRC - FOBT annually + Flex sig every 5 yrs; OR - Colonoscopy every 10 yrs; OR - DCBE every 5 yrs
Slide 42-

CRC Risk Management Moderate/Family history Age to begin 1. Two 1st degree relatives with CRC any age 40 years* or one 1st degree relative with CRC < 60 - Colonoscopy every 5 yrs 2. One 1st degree relative with CRC >60 or 40 years two 2nd degree relatives with CRC any age - Average risk screening * Or 5-10 yrs earlier than earliest case in family Gastroenterology: 2003;124:544-560
Slide 43-

CRC Risk Management Age to Begin HNPCC or suspected HNPCC 20-25 yrs 1. Colonoscopy every 1-2 yrs 2. Genetic counseling; consider genetic testing FAP or suspected FAP 10-12 yrs 1. Flex sig or colonoscopy every1-2 yrs 2. Genetic counseling; consider genetic testing
Slide 44-

ppt slide no 44 content not found
Slide 45-

Cancer Genetic Counseling Full pedigree analysis and risk assessment Discussion of: Personal cancer risks based on family history Genetic testing options and risk of mutation Advantages, risks and limitations of genetic testing Personalized, risk-based screening and prevention options Support resources
Slide 46-

Cancer Genetic Testing: Elements of Informed Consent Information on specific test(s) being considered Implications of positive, negative, uninformative results Options for risk assessment and management without genetic testing Risk of passing a mutation to offspring Technical accuracy of test Fees involved in testing and counseling Option of DNA banking
Slide 47-

Cancer Genetic Testing: Informed Consent (cont.) Psychological implications of test results Risks of insurance/employment discrimination Confidentiality issues Options for and limitations of medical surveillance and strategies for prevention following testing Importance of and guidance on sharing results with at-risk relatives Results disclosure American Society of Clinical Oncology, March, 2003
Slide 48-

Case 1:Joan Joan, age 38, was recently diagnosed with endometrial cancer. Family history reveals: Paternal grandmother: endometrial cancer, age 50 Paternal uncle: colon cancer, age 48 Father: colonoscopy at age 50; four adenomatous polyps removed No other significant history Both sides of the family are Northern European Caucasian
Slide 49-

Pedigree: Case 1 Key: Endometrial CA Colorectal CA Adenomatous polyps Dx 38 Dx 50 88 yr 63 yr 4 polyps 50 yrs. CRC Dx 48 61 yr 38 yr 10 yr 8 yr 35 yr French, Irish, Scottish German, English
Slide 50-

Case 1: Assessment Joan meets Amsterdam II Criteria and is at risk for HNPCC Refer to genetics for cancer genetic counseling and discussion of genetic testing for HNPCC Testing options: Direct gene testing of MLH1 and MSH2 OR MSI/IHC screening of tumor tissue with gene sequencing if MSI positive
Slide 51-

Case 2: Ted Ted is 30 and wants a colonoscopy because his mother was just diagnosed with colon cancer after routine screening at age 54. Family history reveals: Paternal grandfather: died of CRC at age 79. No hx of endometrial, ovarian, small bowel or ureter/kidney cancer on either side of family. Two maternal aunts: cervical cancer at ages 30 & 34 Maternal grandmother: breast cancer age 85
Slide 52-

Case 2: Pedigree 30 yrs 34 yrs Key: CRC Breast CA Cervical CA BrCa 85 yrs d.87 Colon Ca 54 yrs Cerv.Ca 30 yr 55 58 Cerv.Ca 32 yr 60 d. 58 MI 84 56 CRC 79 d.82 Italian Irish German
Slide 53-

Case 2: Ted Verify Diagnoses! Obtain and review pathology reports on all reported cancers, whenever possible If diagnoses are correct: Ted has no family history indicative of a known colon cancer syndrome (HNPCC, FAP, other) Ted’s lifetime risk of colorectal CA is increased 2 to 3 fold due to one affected first degree relative (>50) Moderate/familial risk: Screening by colonoscopy starting at age 40, or 10 yrs earlier than earliest case in family, is reasonable
Slide 54-

Oregon Genetics Providers Portland Oregon Health & Science University Legacy Health Care Northwest Perinatal Services Kaiser-Permanente Eugene Center for Genetics & Maternal Fetal Medicine Bend Genetic Counseling of Central Oregon (cancer only)
Slide 55-

Referral for Genetic Services Consult “Genetic Services Contact List” Phone consultations available: OHSU Genetics Consult Line: 503-494-5516 Refer patients by phone, fax, mail, or patient self-referral ‘Indications for Referral’ in resource packet Preconception/Prenatal Pediatric Adolescent/Adult
Slide 56-

Resource Materials Patient pamphlets: ‘Do You Have Cancer in Your Family?’ ‘Genetic Testing: A Fact Sheet’ Web-based cancer genetics resource list Hereditary Colon Cancer Association www.hereditarycc.org Resource materials at www.healthoregon.org/genetics Genetics tutorials on www.modimes.org